Hyaluronic Acid Turbidimetric Assay Compared to Standard Method
|
By LabMedica International staff writers Posted on 13 Jan 2016 |
|
Image: The Hitachi 917 Automatic Disk-Chemistry Analyzer (Photo courtesy of Roche Diagnostics).
Circulating hyaluronic acid (HA) in human adults is primarily produced in the peripheral soft connective tissue and transported to the systemic circulation via lymph drainage and the majority of HA is removed from circulation by hepatic elimination.
HA is essentially non-immunogenic, which has excluded direct immunochemical methods of measurement. To accommodate this, several advanced methods of measurements have been used including enzymatic degradation; hyaluronic-binding protein (HABP) linked enzyme-linked immunosorbent assay (ELISA) and high-performance liquid chromatography.
Scientists at the Nordsjaellands Hospital, University of Copenhagen, (Denmark) and their colleagues measured HA concentrations in 39 samples of serum from 39 randomly selected intensive care unit (ICU) patients. The HA was measured by a particle-enhanced turbidimetric immunoassay (PETIA) and enzyme-linked immunosorbent assay (ELISA) in a 40-sample dilution series and the 39 ICU patients.
The HA was measured with the PETIA (Corgenix; Broomfield, CO, USA) in ICU samples on the Hitachi 917 (Roche Diagnostics, GmbH; Mannheim, Germany) and in the dilution series on Modular P (Roche Diagnostics GmbH) analyzers (test assay), and by Corgenix HA ELISA using double determination (reference method).
The scientists found that in the ICU patients, the median HA concentration was 159.0 ng/mL (interquartile range (IQR) 117.5–362.5 ng/mL) with ELISA and 157.5 ng/ml (IQR 92.5–359.6 ng/mL) with PETIA. The mean difference was 12.88 ng/mL which was statistically significant and the 95% limits of agreement were −91.17 to 116.9 ng/mL. In the dilution series, the mean difference was −59.26 ng/mL (95% CI, −74.68 to 43.84 ng/mL, and the 95% limits of agreement were 35.23 to −153.8 ng/mL.
The authors concluded that there was random variation between the PETIA and ELISA test that could affect performance in a clinical context. The new clinical biochemistry assay for HA determination will allow for large studies of the clinical utility of HA. The study was published online on December 14, 2015, in the Journal of Clinical Laboratory Analysis.
Related Links:
Nordsjaellands Hospital
Corgenix
Roche Diagnostics GmbH
 Assay.jpg)
HA is essentially non-immunogenic, which has excluded direct immunochemical methods of measurement. To accommodate this, several advanced methods of measurements have been used including enzymatic degradation; hyaluronic-binding protein (HABP) linked enzyme-linked immunosorbent assay (ELISA) and high-performance liquid chromatography.
Scientists at the Nordsjaellands Hospital, University of Copenhagen, (Denmark) and their colleagues measured HA concentrations in 39 samples of serum from 39 randomly selected intensive care unit (ICU) patients. The HA was measured by a particle-enhanced turbidimetric immunoassay (PETIA) and enzyme-linked immunosorbent assay (ELISA) in a 40-sample dilution series and the 39 ICU patients.
The HA was measured with the PETIA (Corgenix; Broomfield, CO, USA) in ICU samples on the Hitachi 917 (Roche Diagnostics, GmbH; Mannheim, Germany) and in the dilution series on Modular P (Roche Diagnostics GmbH) analyzers (test assay), and by Corgenix HA ELISA using double determination (reference method).
The scientists found that in the ICU patients, the median HA concentration was 159.0 ng/mL (interquartile range (IQR) 117.5–362.5 ng/mL) with ELISA and 157.5 ng/ml (IQR 92.5–359.6 ng/mL) with PETIA. The mean difference was 12.88 ng/mL which was statistically significant and the 95% limits of agreement were −91.17 to 116.9 ng/mL. In the dilution series, the mean difference was −59.26 ng/mL (95% CI, −74.68 to 43.84 ng/mL, and the 95% limits of agreement were 35.23 to −153.8 ng/mL.
The authors concluded that there was random variation between the PETIA and ELISA test that could affect performance in a clinical context. The new clinical biochemistry assay for HA determination will allow for large studies of the clinical utility of HA. The study was published online on December 14, 2015, in the Journal of Clinical Laboratory Analysis.
Related Links:
Nordsjaellands Hospital
Corgenix
Roche Diagnostics GmbH
Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay
Immunofluorescence Analyzer
IFA System
Urine Analyzer
respons® UDS100
Latest Immunology News
- Immune Biomarkers May Predict Recurrent Checkpoint Inhibitor Arthritis
- Immune Cell Blood Test May Predict Melanoma Immunotherapy Response
- Study Reveals Viral Protein Driving COVID-19-Related Vascular Injury
- Antibody Profiling Identifies Preclinical Inflammatory Bowel Disease Years Before Diagnosis
- Study Reveals Immune Mechanism Driving Severe COVID-19 Progression
- Ultrasensitive Blood Test Detects Sjögren’s Signature Years Before Diagnosis
- New Assays Expand Cytokine Testing for Transplant and Immunocompromised Patients
- Cell-Free Assay Detects Functional IgE for Food Allergy Diagnosis
- Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19
- Anti-Lipid Antibody Biomarkers May Identify Early Lyme Disease and Persistent Symptoms
- Immune Biomarkers Could Identify Risk of Chronic Critical Illness on ICU Admission
- Emergency Department Opt-Out Testing Program Identifies Undiagnosed HIV
- Airway Immune Signature May Predict Tuberculosis Progression Risk
- New Cellular Biomarkers Correlate with Disease Severity in Sjögren Disease
- Lung Immune Profiling Reveals Distinct Severe Pneumonia Subtypes
- Lab-on-a-Chip Approach Advances Immune–Cancer Cell Interaction Analysis
Channels
Molecular Diagnostics
view channel
New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples
Liquid biopsy seeks to detect tumor-derived signals from small blood samples, but circulating cell-free DNA is scarce and heterogeneous, limiting sensitivity. Combining complementary signals such as methylation,... Read more
Blood Test for Lung Cancer Screening Receives FDA Breakthrough Device Designation
Lung cancer remains the leading cause of cancer death in the United States, yet only about 18% of people eligible for screening undergo low-dose computed tomography, the current guideline-recommended method.... Read more
Hematology
view channel
New Genetic Findings Reveal Cause of Bone Marrow Failure Syndrome
Inherited bone marrow failure syndromes (IBMFS) impair the bone marrow’s ability to produce sufficient healthy blood cells and are associated with an increased risk of early-onset myelodysplastic syndromes (MDS).... Read more
Ultra-Portable Device Enables Finger-Prick Blood Testing at Home
Patients who need frequent blood tests often face repeated clinic visits that burden services and disrupt care. In the UK, millions of tests are performed each year to diagnose disease, guide therapy,... Read more
Immunology
view channel
Immune Biomarkers May Predict Recurrent Checkpoint Inhibitor Arthritis
Inflammatory arthritis is a recognized immune-related adverse event in patients treated with immune checkpoint inhibitors (ICIs) for cancer. Between 20% and 50% of affected patients experience more than... Read more
Immune Cell Blood Test May Predict Melanoma Immunotherapy Response
Melanoma remains one of the deadliest skin cancers, although outcomes improve markedly when the disease is detected early. Immunotherapy has extended survival for many patients with advanced melanoma,... Read more
Microbiology
view channel
Surveillance and Susceptibility Testing Track Rising Candida Auris in U.S.
Drug-resistant fungal infections are straining infection control and treatment in hospitals and long-term care facilities, where rapid transmission can lead to severe outcomes. Candida auris has expanded... Read more
Plasma Cell-Free DNA Test Enables Earlier Diagnosis of Invasive Fungal Infections
Invasive fungal infections disproportionately affect immunocompromised patients, while diagnostic delays can contribute to substantial morbidity and mortality. Existing methods often depend on invasive... Read more
Pathology
view channel
AI Uses H&E Slides to Predict Key Biomarkers Across 32 Cancers
Molecular profiling is essential for characterizing solid tumors, but many laboratories still rely on separate genetic assays to detect alterations such as TP53 mutations. These workflows can be resource-intensive... Read more
AI Tool Identifies Slide Artifacts to Speed Digital Pathology Diagnosis
Pathology laboratories face growing case volumes, staffing pressures, and increasing diagnostic complexity that can delay results. At the same time, whole-slide images may contain quality defects such... Read more
FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis
Rising cancer incidence is colliding with a shrinking pathologist workforce, intensifying pressure on diagnostic turnaround times in clinical laboratories. Many labs are adopting digital pathology to manage... Read more
Technology
view channel
Interoperable Data Platform Standardizes Multi-Cancer Blood Test Results
Proteotype Diagnostics has introduced Alchemi, a proprietary data and clinical workflow platform being developed for Enlighten, the company’s investigational blood-based multi-cancer test.... Read more
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channel
Collaboration Supports Global ADC Development with AI-Powered Tissue Analysis
Selecting patients for antibody-drug conjugates (ADCs) increasingly requires broader tissue context, as target expression alone may not fully explain therapeutic response. Laboratories and translational... Read more
Standardized Staining Technology Advances Digital Pathology Workflows
Digital pathology is increasingly used to streamline cancer diagnostics, yet staining variability can hinder slide interpretation and limit the reliability of artificial intelligence tools.... Read more
Global Testing Service Advances Leukemia MRD Monitoring
KMT2A rearrangements drive aggressive subsets of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) and are associated with relapse and poor outcomes. As menin inhibitors enter clinical... Read more